Lineage Cell Therapeutics
Lineage Cell Therapeutics' revenue rose 53.2% to $15 million in fiscal 2025. Its operating margin was −251.6%, down from −226.1% a year earlier. Free cash flow was −$19 million. The diluted share count rose 14.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Lineage Cell Therapeutics does
Lineage Cell Therapeutics is a clinical-stage biotechnology company that develops cell transplants to replace cells lost to disease or injury, an approach it calls Replace and Restore. It uses stem cells only as source material to make mature, working cells, which are then transplanted into patients. It has no approved products.
Its programs rely on its own manufacturing platform, AlloSCOPE, which creates many vials of donor-derived cells from a single cell line. The main programs are OpRegen, an eye-cell therapy in Phase 2a testing under a worldwide collaboration with Roche and Genentech for geographic atrophy in dry age-related macular degeneration, and OPC1, a spinal cord injury therapy in Phase 1/2a testing. Others include ReSonance for hearing loss, developed with William Demant Invest, and early research on Type 1 diabetes.
The company's revenue so far is mainly collaboration revenue from Roche and William Demant Invest. It says it may advance some programs on its own and partner others.
Its biggest risks, as it describes them
- It has lost money since it began and does not know when, or if, it will be profitable.
- It will need substantial additional funding to complete development and seek approval of its products.
- Its OpRegen revenue and prospects depend on Roche and Genentech, which could end the collaboration.
- Its therapies rely on technology and cell lines licensed from third parties.
- Its therapies are given by surgery, which needs specialized tools and procedures.
Income statement
Lineage Cell Therapeutics lost money in fiscal 2025: a net loss of $64 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 58 | 58 | 36 | 48 | 56 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −3,785.5x | −1,732.3x | −2,473.3x | −2,386.4x | −1,262.7x |
| Current ratio | 2.4x | 3.2x | 2.1x | 3.6x | 5.2x |
| Quick ratio | 2.4x | 3.2x | 2.1x | 3.6x | 5.2x |
Cash flow
Projections
Project Lineage Cell Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Lineage Cell Therapeutics says to expect
- Cash runway
Cash, cash equivalents, and marketable securities of $45.2 million as of September 30, 2026 is expected to support planned operations into Q2 2028.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $878,348 of Lineage Cell Therapeutics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Broadwood Partners L.p.Director, 10% owner | Bought | 1,000,000 | $0.77 | $770,700 | Form 4 |
| Nov 17, 2026 | Michael H. MulroyDirector | Bought | 30,000 | $0.87 | $26,100 | Form 4 |
| Nov 16, 2026 | Brian M CulleyPresident and CEO, Director | Bought | 40,500 | $0.92 | $37,098 | Form 4 |
| Nov 16, 2026 | Deborah J AndrewsDirector | Bought | 25,000 | $0.80 | $20,000 | Form 4 |
| Mar 12, 2026 | Brian M CulleyPresident and CEO, Director | Bought | 15,000 | $1.63 | $24,450 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −366.1% | −242.8% | −80.3% |
| Altman Z'' | −11.07 | −8.51 | −12.27 |
| Accruals ratio | 6.3% | 4.2% | −39.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Lineage Cell Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Lineage Cell Therapeutics | FY25 | 53.2% | −251.6% | −133.6% | — | — | — | |
| Arbutus Biopharma | FY25 | 128.2% | −271.0% | −281.4% | — | — | 3 | Compare |
| Relay Therapeutics | FY25 | 53.4% | −1,971.6% | −1,536.1% | — | — | — | Compare |
| uniQure | FY25 | −40.6% | −1,151.4% | −1,108.2% | — | — | 2 | Compare |
| MediWound | FY25 | −16.1% | −149.0% | −127.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 6 | 4 | 5 | 4 | 2 | 4 | 15 | 9 | 10 | 15 |
| Revenue growth | −15.8% | −41.6% | 44.2% | −29.5% | −48.0% | 137.7% | 238.7% | −39.2% | 6.2% | 53.2% |
| Gross profit | 6 | 3 | 5 | 3 | 1 | 3 | 14 | 8 | 9 | — |
| Research and development | 36 | 24 | 21 | 18 | 12 | 34 | 14 | 16 | 12 | 18 |
| Operating income | −59 | −39 | −42 | −39 | −26 | −49 | −22 | −25 | −22 | −37 |
| Net income | 34 | −20 | −46 | −12 | −21 | −43 | −26 | −22 | −19 | −64 |
| Diluted EPS (US$) | 0.34 | −0.17 | −0.36 | −0.08 | −0.14 | −0.26 | −0.15 | −0.12 | −0.09 | −0.28 |
| Diluted shares (millions) | 100 | 114 | 127 | 146 | 150 | 164 | 170 | 173 | 200 | 230 |
| Cash flow | ||||||||||
| Cash from operations | −42 | −30 | −31 | −32 | −20 | −24 | 1 | −29 | −23 | −19 |
| Capital expenditure | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Free cash flow | −45 | −32 | −31 | −32 | −20 | −24 | 1 | −29 | −24 | −19 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 8 | 4 | 5 | 4 | 2 | 4 | 4 | 5 | 5 | 5 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 12 | 38 | 31 | 31 | 42 | 58 | 58 | 36 | 48 | 56 |
| Debt incl. finance leases | 0 | 0 | — | — | — | — | — | — | — | — |
| Total assets | 143 | 173 | 102 | 126 | 108 | 174 | 124 | 101 | 113 | 113 |
| Total liabilities | 12 | 9 | 9 | 14 | 13 | 84 | 52 | 39 | 36 | 69 |
| Shareholders' equity | 118 | 163 | 94 | 113 | 96 | 92 | 73 | 63 | 78 | 44 |
| Margins and ratios | ||||||||||
| Gross margin | 94.0% | 95.1% | 94.0% | 88.3% | 78.9% | 67.2% | 95.0% | 92.5% | 96.5% | — |
| Operating margin | −995.6% | −1,125.0% | −837.9% | −1,106.0% | −1,448.4% | −1,133.6% | −153.2% | −276.5% | −226.1% | −251.6% |
| Net margin | 566.8% | −577.7% | −922.0% | −333.1% | −1,130.8% | −991.0% | −178.7% | −240.2% | −195.9% | −436.5% |
| Free cash flow margin | −752.6% | −920.9% | −630.3% | −921.4% | −1,085.3% | −550.6% | 4.4% | −326.9% | −249.1% | −133.6% |
| Rule of 40 (growth + FCF margin) | −768.4% | −962.5% | −586.0% | −950.9% | −1,133.3% | −412.9% | 243.1% | −366.1% | −242.8% | −80.3% |
| Return on capital | −61.0% | −25.1% | — | — | — | — | — | — | — | — |
| Return on equity | 46.7% | −14.2% | −35.9% | −11.3% | −19.7% | −45.7% | −31.7% | −31.4% | −26.2% | −103.4% |
| Return on assets | 28.3% | −12.7% | −33.5% | −10.3% | −17.7% | −30.5% | −17.6% | −19.1% | −17.4% | −56.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |